The Fertility Show, Manchester Central, 24-25 March 2018
Page URL:

China begins first CRISPR human therapy trial

21 November 2016
Appeared in BioNews 878

Chinese scientists have injected CRISPR/Cas9 gene-edited cells into a human for the first time.

The patient, who has non-small-cell lung cancer, received the modified cells as part of a clinical trial at the Sichuan University West China Hospital in Chengdu (see BioNews 861).

This is the first of several CRISPR clinical trials that are planned in China and in the US, all aimed at treating various cancers. The US trial, which will be funded by Facebook billionaire Sean Parker, is due to begin in 2017 at the University of Pennsylvania (see BioNews 857).

'I think this is going to trigger Sputnik 2.0, a biomedical duel on progress between China and the United States, which is important since competition usually improves the end product,' Professor Carl June, who will lead the US trial, told Nature News.

The team from China extracted immune T cells from the patient's blood, and used CRISPR/Cas9 to delete the gene that produces PD-1, a protein that keeps the immune response in check. PD-1 inadvertently helps cancerous cells as it tempers the response of T cells that would otherwise attack them. The modified cells were cultured and then injected back into the patient.

Oncologist Dr Lu You, who is leading the trial, said that the treatment went smoothly and the patient has been given a second injection. Each participant will receive between two and four injections in total. The focus of the clinical trial is to establish the safety of the technique, and all ten participants will be monitored closely.

Trials involving PD-1 antibodies, which would operate in the same way to take the brakes off the immune system have shown some promise. Dr Naiyer Rizvi of Columbia University Medical Centre, says he doubts whether the CRISPR-modified cells will work any better than the antibodies, which can be produced in unlimited numbers.

He told Nature News: 'It's an exciting strategy. The rationale is strong.' But he added that process of extracting, genetically modifying and multiplying cells is 'a huge undertaking and not very scalable'. 'Unless it shows a large gain in efficacy, it will be hard to justify moving forward,' he concluded.

On Wednesday 7 December 2017, genome editing and embryo research will be debated at the Progress Educational Trust's public conference 'Rethinking the Ethics of Embryo Research: Genome Editing, 14 Days and Beyond'.

Click here for full for full details, including the conference agenda and how to book your tickets, and email with any queries.

19 June 2017 - by Charlotte Spicer 
Two major biotech companies have criticised a recent study that claimed CRISPR may cause hundreds of unwanted mutations...
5 June 2017 - by Emma Lamb 
Two teams of doctors in China are to administer embryonic stem cell therapy from fertilised human embryos to treat different degenerative diseases...
5 June 2017 - by Charlotte Spicer 
CRISPR may introduce hundreds of unwanted mutations into the genome, a small study finds...
8 May 2017 - by Sarah Pritchard 
Aggressive human prostate and liver tumours have been shrunk in mice by targeting a ‘fused’ gene mutation using CRISPR/Cas9...
27 March 2017 - by Emma Laycock 
Radiolab explores the science, the uses and the ethics of CRISPR in this podcast that was two years in the making...
13 March 2017 - by Dr Katie Howe 
Chinese scientists have successfully used genome editing to correct mutations in viable human embryos for the first time...
26 September 2016 - by Anneesa Amjad 
A scientist in Sweden has become the first to edit genes in healthy human embryos...
25 July 2016 - by Rachel Siden 
Chinese scientists plan to start the first-ever clinical trial of CRISPR genome-editing technology in humans – on patients with lung cancer – this August...
27 June 2016 - by Rachel Reeves 
The first in-human use of the genome-editing technology CRISPR has been approved by a US federal safety board...
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.